Table 1:
Patient characteristics (N=33,232)
| Total population | Patients who died | |
|---|---|---|
| N (%) | N (%) | |
| Total | 33232 (100.0) | 1518 (100.0) |
| Sex | ||
| Female | 10173 (30.6) | 301 (19.8) |
| Male | 23059 (69.4) | 1217 (80.2) |
| Age at ART initiation (years) | ||
| ≤40 | 23151 (69.7) | 919 (60.5) |
| 41–50 | 6839 (20.6) | 314 (20.7) |
| >50 | 3242 (9.8) | 285 (18.8) |
| Median (IQR) | 36 (30–42) | 38 (32–46) |
| HIV exposure category | ||
| Heterosexual | 19492 (58.7) | 1151 (75.8) |
| MSM | 3216 (9.7) | 99 (6.5) |
| IDU | 1214 (3.7) | 132 (8.7) |
| Other/unknown | 9310 (28.0) | 136 (9.0) |
| Pre-ART HIV viral load (copies/mL) | ||
| <1000 | 473 (1.4) | 11 (0.7) |
| ≥1000 | 6033 (18.2) | 324 (21.3) |
| Missing/not tested | 26726 (80.4) | 1183 (77.9) |
| Median log (IQR) | 5.0 (4.4–5.5) | 5.2 (4.8–5.7) |
| Pre-ART CD4 count (cells/μL) | ||
| <200 | 14182 (42.7) | 1028 (67.7) |
| 200–349 | 5933 (17.9) | 122 (8.0) |
| 350–499 | 1871 (5.6) | 24 (1.6) |
| ≥500 | 1254 (3.8) | 22 (1.4) |
| Missing/not tested | 9992 (30.1) | 322 (21.2) |
| Median (IQR) | 154 (59–268) | 65 (27–147) |
| ART initiation year | ||
| Median (IQR) | 2010 (2006–2012) | 2007 (2005–2011) |
| Positive HBsAg* | ||
| No | 17349 (52.2) | 785 (51.7) |
| Yes | 1555 (4.7) | 126 (8.3) |
| Missing/not tested | 14328 (43.1) | 607 (40.0) |
| Positive anti-HCV* | ||
| No | 12275 (36.9) | 660 (43.5) |
| Yes | 1673 (5.0) | 160 (10.5) |
| Missing/not tested | 19284 (58.0) | 698 (46.0) |
| Pre-ART FPG (mmol/L) | ||
| Normal | 4649 (14.0) | 231 (15.2) |
| Prediabetes | 919 (2.8) | 53 (3.5) |
| Diabetes | 344 (1.0) | 28 (1.8) |
| Missing/not tested | 27320 (82.2) | 1206 (79.4) |
| Median (IQR) | 4.8 (4.3–5.4) | 4.9 (4.4–5.6) |
ART, antiretroviral therapy; IQR, interquartile range; FPG, fasting plasma glucose; MSM, men who have sex with men; IDU, injecting drug use.
*
HBsAg and anti-HCV test on ever tested positive throughout follow-up.